✦ LIBER ✦

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

✍ Scribed by Maetzel, Andreas ;Strand, Vibeke ;Tugwell, Peter ;Wells, George ;Bombardier, Claire

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 88 KB
Volume: 47
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.10793

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of biologics in polya

Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs

✍ Wendy J. Ungar; Vania Costa; Rebecca Hancock-Howard; Brian M. Feldman; Ronald M. 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 150 KB 👁 2 views

## Abstract ## Objective Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and can have long‐term effects leading to disability in adulthood. Biologics are a new class of drugs increasingly used to treat JIA. The primary study objective was to determine the

Cost-effectiveness of biologic response

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

✍ Gabrielle van der Velde; Ba' Pham; Márcio Machado; Luciano Ieraci; William Witte 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 172 KB 👁 1 views

Five-year followup of rheumatoid arthrit

Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year

✍ Suzan M. M. Verstappen; Johannes W. G. Jacobs; Johannes W. J. Bijlsma; Anton H. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## Objective To evaluate whether the clinical advantages observed after 1 year in a randomized controlled clinical trial, in which 2 treatment strategies were compared (the early disease‐modifying antirheumatic drug [DMARD] approach versus the pyramid approach), persist after 5 years.

Retardation of joint damage in patients

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study

✍ Markku Korpela; Leena Laasonen; Pekka Hannonen; Hannu Kautiainen; Marjatta Leiri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

## Abstract ## Objective To evaluate the long‐term frequency of disease remissions and the progression of joint damage in patients with early rheumatoid arthritis (RA) who were initially randomized to 2 years of treatment with either a combination of 3 disease‐modifying antirheumatic drugs (DMARDs

Impact of initial aggressive drug treatm

Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five-year randomized followup trial

✍ Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## Objective To compare the efficacy of therapy with a combination of disease‐modifying antirheumatic drugs (DMARDs) versus therapy with a single DMARD in the prevention of work disability in patients with early rheumatoid arthritis (RA). ## Methods In the Finnish Rheumatoid Arthriti

Safety of the selective costimulation mo

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

✍ M. Weinblatt; B. Combe; A. Covucci; R. Aranda; J. C. Becker; E. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views